NGeneBio Co., Ltd. is a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx), which develops and provides next generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW). NGeneBio was founded in October 2015, headquartered in Seoul, South Korea as a joint venture between Genecurix and Korea Telecom. The company launched NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTestTM) with clinical analysis SW (NGeneAnalysisTM) in 2016. BRCA NGS panel for PARP inhibitor CDx test and solid tumor/hematologic cancer NGS panels will be launched, inclusive of clinical data analysis SW platform. The mission of the company is to provide clinically validated NGS based IVD/CDx products/services with convergence of innovative bioinformatics and SW development capacity for global market. For more information, visit www.ngenebio.com.
View Top Employees from NGeneBio Co., Ltd.Website | http://www.ngenebio.com |
Revenue | $5 million |
Funding | $32 million |
Employees | 24 (23 on RocketReach) |
Founded | 2015 |
Address | #303-307 904ho 288, Guro-gu, Seoul, KR |
Phone | (822) 867-9798 |
Technologies |
JavaScript,
HTML,
PHP
+13 more
(view full list)
|
Industry | Medical Equipment Manufacturing, Business Services General, Diagnostic Equipment, Business Services, Other Healthcare Technology Systems |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 541715 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies |
Looking for a particular NGeneBio Co., Ltd. employee's phone or email?
The NGeneBio Co., Ltd. annual revenue was $5 million in 2024.
William Yang is the Director Corporate Strategy of NGeneBio Co., Ltd..
23 people are employed at NGeneBio Co., Ltd..
NGeneBio Co., Ltd. is based in Guro-gu, Seoul.
The NAICS codes for NGeneBio Co., Ltd. are [5417, 541715, 54, 541, 54171].
The SIC codes for NGeneBio Co., Ltd. are [873, 87].